Whittier Trust Co. Has $713,000 Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Whittier Trust Co. raised its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,533 shares of the pharmaceutical company’s stock after buying an additional 86 shares during the quarter. Whittier Trust Co.’s holdings in Vertex Pharmaceuticals were worth $713,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Sunbelt Securities Inc. grew its holdings in Vertex Pharmaceuticals by 47.2% during the first quarter. Sunbelt Securities Inc. now owns 1,749 shares of the pharmaceutical company’s stock valued at $731,000 after purchasing an additional 561 shares during the period. Brookstone Capital Management grew its holdings in shares of Vertex Pharmaceuticals by 11.1% in the 1st quarter. Brookstone Capital Management now owns 2,368 shares of the pharmaceutical company’s stock valued at $990,000 after buying an additional 237 shares during the period. Future Financial Wealth Managment LLC bought a new stake in shares of Vertex Pharmaceuticals in the 1st quarter valued at $42,000. DGS Capital Management LLC acquired a new stake in Vertex Pharmaceuticals during the 1st quarter worth $277,000. Finally, Wealthcare Advisory Partners LLC lifted its holdings in Vertex Pharmaceuticals by 4.6% during the first quarter. Wealthcare Advisory Partners LLC now owns 3,218 shares of the pharmaceutical company’s stock worth $1,345,000 after acquiring an additional 141 shares in the last quarter. Institutional investors own 90.96% of the company’s stock.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, Director Bruce I. Sachs sold 5,295 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $508.00, for a total value of $2,689,860.00. Following the transaction, the director now directly owns 40,000 shares of the company’s stock, valued at $20,320,000. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Bruce I. Sachs sold 5,295 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $508.00, for a total value of $2,689,860.00. Following the transaction, the director now owns 40,000 shares of the company’s stock, valued at approximately $20,320,000. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Carmen Bozic sold 2,280 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $476.75, for a total value of $1,086,990.00. Following the sale, the chief marketing officer now directly owns 23,259 shares of the company’s stock, valued at approximately $11,088,728.25. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 12,005 shares of company stock valued at $5,988,066 in the last quarter. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Stock Down 1.0 %

Shares of VRTX stock opened at $470.05 on Thursday. Vertex Pharmaceuticals Incorporated has a 52-week low of $341.90 and a 52-week high of $510.64. The stock has a market cap of $121.30 billion, a price-to-earnings ratio of 30.50 and a beta of 0.40. The firm’s 50-day moving average is $475.60 and its 200-day moving average is $461.29. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.26 and a current ratio of 2.52.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($12.54) by ($0.29). Vertex Pharmaceuticals had a negative net margin of 4.74% and a negative return on equity of 2.45%. The business had revenue of $2.65 billion during the quarter, compared to the consensus estimate of $2.66 billion. During the same quarter in the prior year, the company earned $3.53 EPS. Vertex Pharmaceuticals’s quarterly revenue was up 6.1% on a year-over-year basis. Sell-side analysts predict that Vertex Pharmaceuticals Incorporated will post -2.11 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on VRTX shares. Piper Sandler raised their price target on Vertex Pharmaceuticals from $500.00 to $535.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Raymond James reaffirmed a “market perform” rating on shares of Vertex Pharmaceuticals in a research note on Thursday, October 10th. Needham & Company LLC reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Friday, July 26th. Bank of America cut their price objective on shares of Vertex Pharmaceuticals from $550.00 to $541.00 and set a “buy” rating on the stock in a research report on Monday, October 14th. Finally, Barclays cut Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and increased their target price for the stock from $472.00 to $509.00 in a report on Monday, August 5th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, Vertex Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $492.92.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.